This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


6mhm

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (06:32, 11 October 2023) (edit) (undo)
 
Line 3: Line 3:
<StructureSection load='6mhm' size='340' side='right'caption='[[6mhm]], [[Resolution|resolution]] 2.74&Aring;' scene=''>
<StructureSection load='6mhm' size='340' side='right'caption='[[6mhm]], [[Resolution|resolution]] 2.74&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[6mhm]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MHM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MHM FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[6mhm]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MHM OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6MHM FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=JRY:hexylcarbamic+acid'>JRY</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.743&#8491;</td></tr>
-
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ASAH1, ASAH, HSD-33, HSD33 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=JRY:hexylcarbamic+acid'>JRY</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PRD_900017:triacetyl-beta-chitotriose'>PRD_900017</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Ceramidase Ceramidase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.5.1.23 3.5.1.23] </span></td></tr>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6mhm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6mhm OCA], [https://pdbe.org/6mhm PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6mhm RCSB], [https://www.ebi.ac.uk/pdbsum/6mhm PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6mhm ProSAT]</span></td></tr>
-
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6mhm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6mhm OCA], [http://pdbe.org/6mhm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6mhm RCSB], [http://www.ebi.ac.uk/pdbsum/6mhm PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6mhm ProSAT]</span></td></tr>
+
</table>
</table>
== Disease ==
== Disease ==
-
[[http://www.uniprot.org/uniprot/ASAH1_HUMAN ASAH1_HUMAN]] Farber disease;Spinal muscular atrophy-progressive myoclonic epilepsy syndrome. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry.
+
[https://www.uniprot.org/uniprot/ASAH1_HUMAN ASAH1_HUMAN] Farber disease;Spinal muscular atrophy-progressive myoclonic epilepsy syndrome. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry.
== Function ==
== Function ==
-
[[http://www.uniprot.org/uniprot/ASAH1_HUMAN ASAH1_HUMAN]] Lysosomal ceramidase that hydrolyzes sphingolipid ceramides into sphingosine and free fatty acids at acidic pH (PubMed:10610716, PubMed:7744740, PubMed:15655246, PubMed:11451951). Ceramides, sphingosine, and its phosphorylated form sphingosine-1-phosphate are bioactive lipids that mediate cellular signaling pathways regulating several biological processes including cell proliferation, apoptosis and differentiation (PubMed:10610716). Has a higher catalytic efficiency towards C12-ceramides versus other ceramides (PubMed:7744740, PubMed:15655246). Also catalyzes the reverse reaction allowing the synthesis of ceramides from fatty acids and sphingosine (PubMed:12764132, PubMed:12815059). For the reverse synthetic reaction, the natural sphingosine D-erythro isomer is more efficiently utilized as a substrate compared to D-erythro-dihydrosphingosine and D-erythro-phytosphingosine, while the fatty acids with chain lengths of 12 or 14 carbons are the most efficiently used (PubMed:12764132). Has also an N-acylethanolamine hydrolase activity (PubMed:15655246). By regulating the levels of ceramides, sphingosine and sphingosine-1-phosphate in the epidermis, mediates the calcium-induced differentiation of epidermal keratinocytes (PubMed:17713573). Also indirectly regulates tumor necrosis factor/TNF-induced apoptosis (By similarity). By regulating the intracellular balance between ceramides and sphingosine, in adrenocortical cells, probably also acts as a regulator of steroidogenesis (PubMed:22261821).[UniProtKB:Q9WV54]<ref>PMID:10610716</ref> <ref>PMID:11451951</ref> <ref>PMID:12764132</ref> <ref>PMID:12815059</ref> <ref>PMID:15655246</ref> <ref>PMID:17713573</ref> <ref>PMID:22261821</ref> <ref>PMID:7744740</ref> <ref>PMID:10610716</ref> Isoform 2: May directly regulate steroidogenesis by binding the nuclear receptor NR5A1 and negatively regulating its transcriptional activity.<ref>PMID:22927646</ref>
+
[https://www.uniprot.org/uniprot/ASAH1_HUMAN ASAH1_HUMAN] Lysosomal ceramidase that hydrolyzes sphingolipid ceramides into sphingosine and free fatty acids at acidic pH (PubMed:10610716, PubMed:7744740, PubMed:15655246, PubMed:11451951). Ceramides, sphingosine, and its phosphorylated form sphingosine-1-phosphate are bioactive lipids that mediate cellular signaling pathways regulating several biological processes including cell proliferation, apoptosis and differentiation (PubMed:10610716). Has a higher catalytic efficiency towards C12-ceramides versus other ceramides (PubMed:7744740, PubMed:15655246). Also catalyzes the reverse reaction allowing the synthesis of ceramides from fatty acids and sphingosine (PubMed:12764132, PubMed:12815059). For the reverse synthetic reaction, the natural sphingosine D-erythro isomer is more efficiently utilized as a substrate compared to D-erythro-dihydrosphingosine and D-erythro-phytosphingosine, while the fatty acids with chain lengths of 12 or 14 carbons are the most efficiently used (PubMed:12764132). Has also an N-acylethanolamine hydrolase activity (PubMed:15655246). By regulating the levels of ceramides, sphingosine and sphingosine-1-phosphate in the epidermis, mediates the calcium-induced differentiation of epidermal keratinocytes (PubMed:17713573). Also indirectly regulates tumor necrosis factor/TNF-induced apoptosis (By similarity). By regulating the intracellular balance between ceramides and sphingosine, in adrenocortical cells, probably also acts as a regulator of steroidogenesis (PubMed:22261821).[UniProtKB:Q9WV54]<ref>PMID:10610716</ref> <ref>PMID:11451951</ref> <ref>PMID:12764132</ref> <ref>PMID:12815059</ref> <ref>PMID:15655246</ref> <ref>PMID:17713573</ref> <ref>PMID:22261821</ref> <ref>PMID:7744740</ref> <ref>PMID:10610716</ref> Isoform 2: May directly regulate steroidogenesis by binding the nuclear receptor NR5A1 and negatively regulating its transcriptional activity.<ref>PMID:22927646</ref>
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 22: Line 21:
</div>
</div>
<div class="pdbe-citations 6mhm" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 6mhm" style="background-color:#fffaf0;"></div>
 +
 +
==See Also==
 +
*[[Ceramidase 3D PDB structures|Ceramidase 3D PDB structures]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Ceramidase]]
+
[[Category: Homo sapiens]]
-
[[Category: Human]]
+
[[Category: Large Structures]]
[[Category: Large Structures]]
-
[[Category: Dementiev, A]]
+
[[Category: Dementiev A]]
-
[[Category: Doan, N]]
+
[[Category: Doan N]]
-
[[Category: Joachimiak, A]]
+
[[Category: Joachimiak A]]
-
[[Category: Acid ceramidase]]
+
-
[[Category: Acid ceramidase inhibitor]]
+
-
[[Category: Benzoxazolone carboxamide]]
+
-
[[Category: Carmofur]]
+
-
[[Category: Hydrolase]]
+

Current revision

Crystal structure of human acid ceramidase in covalent complex with carmofur

PDB ID 6mhm

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/6mhm"
Personal tools